Our results suggest that in HER2-amplified early breast cancer, the exact HER2/CEP17 ratio is an independent, relevant tumor parameter for stratifying patients for neoadjuvant therapy de-escalation. This evidence concerns the gene ERBB2 and breast carcinoma.